Third Harmonic Bio Inc (THRD) concluded trading on Wednesday at a closing price of $13.50, with 4.17 million shares of worth about $56.27 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 48.19% during that period and on September 18, 2024 the price saw a gain of about 5.88%. Currently the company’s common shares owned by public are about 40.10M shares, out of which, 15.38M shares are available for trading.
Stock saw a price change of 3.85% in past 5 days and over the past one month there was a price change of 13.26%. Year-to-date (YTD), THRD shares are showing a performance of 23.06% which increased to 128.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.76 but also hit the highest price of $16.94 during that period. The average intraday trading volume for Third Harmonic Bio Inc shares is 80.00K. The stock is currently trading 9.29% above its 20-day simple moving average (SMA20), while that difference is up 11.16% for SMA50 and it goes to 19.61% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Third Harmonic Bio Inc (NASDAQ: THRD) currently have 40.10M outstanding shares and institutions hold larger chunk of about 45.30% of that.
The stock has a current market capitalization of $554.85M and its 3Y-monthly beta is at 2.84. It has posted earnings per share of -$0.82 in the same period. It has Quick Ratio of 41.13 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for THRD, volatility over the week remained 7.30% while standing at 6.32% over the month.
Stock’s fiscal year EPS is expected to drop by -42.02% while it is estimated to decrease by -32.95% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on August 09, 2024 offering an Overweight rating for the stock and assigned a target price range of between $12 and $20 to it. Coverage by Stifel stated Third Harmonic Bio Inc (THRD) stock as a Buy in their note to investors on June 18, 2024, suggesting a price target of $23 for the stock. On June 07, 2024, Raymond James Initiated their recommendations, while on December 16, 2022, Jefferies Downgrade their ratings for the stock with a price target of $3.60. Stock get an Equal-weight rating from Morgan Stanley on December 15, 2022.
